Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:45:52 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:BNTX from 2023-05-03 to 2024-05-02 - 45 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 06:45U:BNTXNews ReleaseBioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
2024-04-07 14:00U:BNTXNews ReleaseThree-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
2024-03-20 06:15U:BNTXNews ReleaseBioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
2024-03-20 06:00U:BNTXNews ReleaseBioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
2024-03-11 07:45U:BNTXNews ReleaseBioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
2024-03-07 06:45U:BNTXNews ReleaseBioNTech Announces Planned Retirement of Sean Marett
2024-03-06 06:45U:BNTXNews ReleaseBioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
2024-02-17 10:30U:BNTXNews ReleaseROSEN, LEADING INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-02-08 05:45U:BNTXNews ReleaseBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs ‚  
2024-02-08 05:45U:BNTXNews ReleaseBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs ‚   ‚  
2024-01-31 06:45U:BNTXNews ReleaseBioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
2024-01-22 11:04U:BNTXNews ReleaseROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-22 06:45U:BNTXNews ReleaseBioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
2024-01-21 09:04U:BNTXNews ReleaseROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-20 10:05U:BNTXNews ReleaseROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-19 15:06U:BNTXNews ReleaseROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-18 16:05U:BNTXNews ReleaseROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
2024-01-16 15:15U:BNTXNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
2024-01-09 06:45U:BNTXNews ReleaseBioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 08:00U:BNTXNews ReleaseBioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
2023-12-18 13:15U:BNTXNews ReleaseBioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
2023-12-12 06:45U:BNTXNews ReleaseBioNTech to Inaugurate First African Site on December 18, 2023
2023-12-02 14:56U:BNTXNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTX
2023-11-06 06:45U:BNTXNews ReleaseBioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
2023-10-26 06:45U:BNTXNews ReleasePfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
2023-10-26 06:45U:BNTXNews ReleasePfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
2023-10-23 11:30U:BNTXNews ReleaseBioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
2023-10-23 06:45U:BNTXNews ReleaseBioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
2023-10-19 06:45U:BNTXNews ReleaseBioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
2023-10-16 03:30U:BNTXNews ReleaseBioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
2023-10-16 03:00U:BNTXNews ReleaseUpdate Regarding Pfizer ¢ € ™s Statement on COMIRNATY-Related Write-Offs
2023-09-28 14:34U:BNTXNews ReleasePfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
2023-09-28 14:34U:BNTXNews ReleasePfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
2023-09-28 12:24U:BNTXNews ReleasePfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
2023-09-18 06:45U:BNTXNews ReleaseBioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI ¢ € ™s 100 Days Mission
2023-09-11 13:50U:BNTXNews ReleasePfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
2023-08-30 10:00U:BNTXNews ReleasePfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
2023-08-30 10:00U:BNTXNews ReleasePfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
2023-08-14 06:45U:BNTXNews ReleaseBioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
2023-08-07 06:00U:BNTXNews ReleaseBioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
2023-07-31 08:00U:BNTXNews ReleaseBioNTech Completes Acquisition of InstaDeep
2023-07-24 06:45U:BNTXNews ReleaseBioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
2023-06-29 06:45U:BNTXNews ReleaseBioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
2023-06-02 06:45U:BNTXNews ReleaseBioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
2023-05-08 06:45U:BNTXNews ReleaseBioNTech Announces First Quarter 2023 Financial Results and Corporate Update